Doris Schmidt
- Cancer Research top 2%
- Cancer-related molecular mechanisms research 14
- MicroRNA in disease regulation 8
- Molecular Biology top 10%
- RNA modifications and cancer 15
- Renal and related cancers 9
- Epigenetics and DNA Methylation 8
- Drug Discovery top 10%
-
- Renal cell carcinoma treatment 10
- Ferroptosis and cancer prognosis 8
-
- Bladder and Urothelial Cancer Treatments 11
- Co-authors
- Stefan C. MüllerJörg EllingerGlen KristiansenSven PernerMario C. DengYuri TolkachNiklas KlümperFrank Perabo
- Journals
- Urologic Oncology Seminars and Original Investigations (4 papers)Clinical Epigenetics (2 papers)Scientific Reports (2 papers)
- Partner nations
- GermanyChinaSwitzerland
In The Last Decade
Doris Schmidt
68 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 96
- Cancer Research 663
- Molecular Biology 1.0k
- Drug Discovery 2
- Pulmonary and Respiratory Medicine 287
- Oncology 191
Countries citing papers authored by Doris Schmidt
This map shows the geographic impact of Doris Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris Schmidt more than expected).
Fields of papers citing papers by Doris Schmidt
This network shows the impact of papers produced by Doris Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris Schmidt. The network helps show where Doris Schmidt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Doris Schmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 3 | |
| 2 | 2020 | 7 | |
| 3 | 2020 | 6 | |
| 4 | 2018 | 79 | |
| 5 | 2018 | 27 | |
| 6 | 2018 | 25 | |
| 7 | 2017 | 50 | |
| 8 | 2017 | 4 | |
| 9 | 2015 | 41 | |
| 10 | 2015 | 27 | |
| 11 | 2008 | 0 | |
| 12 | Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. | 2006 | 36 |
| 13 | Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. | 2005 | 32 |
| 14 | 2001 | 29 | |
| 15 | 2001 | 20 | |
| 16 | 2000 | 16 | |
| 17 | 1996 | 2 | |
| 18 | 1995 | 6 | |
| 19 | 1994 | 0 | |
| 20 | 1994 | 5 |
About Doris Schmidt
Doris Schmidt is a scholar working on Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine, Biotechnology and Oncology, having authored 72 papers that have together received 1.4k indexed citations. Recurring topics across this work include RNA modifications and cancer (15 papers), Cancer-related molecular mechanisms research (14 papers), Bladder and Urothelial Cancer Treatments (11 papers), Renal cell carcinoma treatment (10 papers), Renal and related cancers (9 papers), MicroRNA in disease regulation (8 papers), Ferroptosis and cancer prognosis (8 papers) and Epigenetics and DNA Methylation (8 papers). The work is most often cited by research in Cancer Research (663 citations), Molecular Biology (1.0k citations), Drug Discovery (2 citations), Pulmonary and Respiratory Medicine (287 citations) and Oncology (191 citations). Doris Schmidt has collaborated with scholars based in Germany, China and Switzerland. Frequent co-authors include Stefan C. Müller, Jörg Ellinger, Glen Kristiansen, Sven Perner, Mario C. Deng, Yuri Tolkach, Niklas Klümper, Frank Perabo, Isabella Syring and Andreas Wirger. Their work appears in journals such as Urologic Oncology Seminars and Original Investigations, Clinical Epigenetics, Scientific Reports, European Urology Focus and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.